Understanding how patients with heart failure with preserved ejection fraction (HFPEF) die provides insight into the natural history and pathophysiology of this complex syndrome, thereby allowing ...

The role of ACE inhibitors in the management of HFPEF is less significant compared with their role in the management of heart failure with left ventricular systolic dysfunction. For patients with ...

Cardiovascular disease, sometimes abbreviated as CVD, is the leading cause of death worldwide. It’s a catchall term for heart ...

TX45 is being evaluated in the APEX phase 2 clinical trial (NCT06616974) in patients with Group 2 Pulmonary Hypertension in Heart Failure with Preserved Ejection Fraction (“PH-HFpEF”). The trial is ...

The challenge for Bayer will be carving out a role for Kerendia in mildly reduced (HFmrEF) or preserved ejection fraction (HFpEF) heart failure alongside SGLT2 inhibitors – AstraZeneca's Farxiga ...

Risk for heart failure events is decreased and health status is improved in patients with HFmrEF and HFpEF receiving finerenone.

Oct. 30, 2024 — New research suggests older adults wait 3-6 months after a heart attack before elective noncardiac surgery to reduce the risk of serious complications like stroke or another heart ...

Results of Tenax Therapeutics’ Phase 2 HELP study of levosimendan in patients with pulmonary hypertension (PH) with heart failure with preserved ejection fraction (HFpEF) demonstrated that IV ...

Although finerenone has kidney protective effects in patients with chronic kidney disease and type 2 diabetes, it does not appear to slow kidney function decline in patients with heart failure with ...

FDA approved the Varipulse pulsed field ablation (PFA) platform for drug refractory paroxysmal atrial fibrillation, Johnson & ...

The European Research Council is funding a consortium consisting of the Helmholtz-Zentrum Hereon, ETH Zurich and TU Graz with ...

in patients with Group 2 Pulmonary Hypertension in Heart Failure with Preserved Ejection Fraction (“PH-HFpEF”). The trial is designed to evaluate efficacy in the broad PH-HFpEF population and enrich ...